Cartesian Therapeutics, Inc. — Form 8-K Summary
Reporting date: September 29, 2026. The filing reports additional retreatment data from the Phase 2 Descartes-08 trial in patients with myasthenia gravis (MG). It is a clinical update, not a periodic financial report.
Clinical data
- The observations cover five participants whose MG symptoms recurred, defined as MG-ADL score of 6 or higher, after 12-month follow-up from their initial Descartes-08 treatment course.
- Retreatment occurred a median of 16.6 months after completion of initial treatment. The company reported greater symptom improvement after retreatment than after the initial course, with mean MG-ADL improvement sustained through 12 months following retreatment.
- At Month 12 after retreatment, average reductions from baseline were 6.6 points (±4.2) on MG-ADL and 15 points (±6.2) on the Myasthenia Gravis Composite (MGC).
- All five participants had clinically meaningful reductions in both MGC and MG-ADL scores. Four maintained a clinically meaningful MG-ADL reduction through Month 12.
Safety, outlook, and considerations
- The company described retreatment as generally well tolerated through Month 12. Reported adverse events were transient and mild; no serious adverse events were reported during retreatment.
- No cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenias, or hypogammaglobulinemia were reported in the retreatment observations.
- The company said the data support the potential for retreatment after MG symptom recurrence. The filing provides no regulatory or commercial guidance and states that the company undertakes no obligation to update the attached materials except as required by law.
- The results are from five participants, so the scope of these observations is limited. The filing does not provide financial results, revenue, cash flow, debt, liquidity, or margins.
Important facts for investors to verify
- Confirm the underlying press release and trial materials for participant-level results, analysis methods, and follow-up details.
- Monitor larger or longer-term datasets for durability of retreatment benefit and safety.
- Review subsequent company disclosures for trial, regulatory, financing, and cash-runway updates.